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71 
BUYERS IN THE BABY MARKET: TOWARD A 
TRANSPARENT CONSUMERISM 
June Carbone & Jody Lyneé Madeira
*
 
Abstract: This Article assesses the forces on the horizon remaking the fertility industry, 
including greater consolidation in the health care industry, the prospects for expanding (or 
contracting) insurance coverage, the likely sources of funding for future innovation in the 
industry, and the impact of globalization and fertility tourism. It concludes that concentration 
in the American market, in contrast with other medical services, may not necessarily raise 
prices, and price differentiation may proceed more from fertility tourism than from 
competition within a single geographic region. The largest challenge may be linking those 
who would fund innovation, whether innovation that produces new high cost products or 
innovations making fertility services more accessible and affordable, with the constantly 
shifting market niches of a globalized era.  
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INTRODUCTION 
Health care today, taken as a whole, is often characterized by the 
increasing consolidation of health care providers, opaque payment 
systems in which neither doctors nor patients understand the full price of 
medical procedures, and increasing distance between doctors and 
patients. 
Yet, certain segments of the health care industry such as cosmetic 
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surgery, many dental and mental health services, and most of assisted 
reproduction, have until recently defied the trends. They did so in large 
part because insurance and government subsidies cover a much smaller 
portion of these procedures. Instead, these services have usually 
occurred in the context of relatively small or solo practices, or university 
centers where patients pay for the services they receive with much less 
(if any) subsidization or third party involvement, and deal directly with 
individual professionals in the process. As a result, market forces 
influence supply and demand much more directly than in other parts of 
the health care industry, and the health care provider-patient relationship 
is a more commercially driven seller-buyer one. 
These forces—particularly the absence of wide scale insurance or 
government subsidization—have shaped assisted reproduction 
technologies (ART) from their inception. Almost every aspect of ART 
has been controversial, from the initial use of artificial insemination with 
donor sperm (AID), to use of fertility drugs that increase the frequency 
of multiple births, to in vitro fertilization (IVF), which permits 
conception outside of the human body. The Catholic Church, for 
instance, identifies human dignity with conception by a married couple 
within a woman’s body, and it therefore opposes IVF—and government 
subsidization of IVF—altogether.1 Others have expressed concern about 
the health effects of fertility drugs, the hormones used in IVF, the 
increased incidence of multiples, and other ART practices.
2
 The 
combination of religious objections to the procedures, and concern that 
government inquiries would result in restrictive measures, have blocked 
inclusion of ART in national health legislation and funding for research 
that would contribute to better understandings of the long term health 
risks involved with these procedures.
3
 Instead, relatively little regulatory 
oversight exists and only a small number of states mandate any form of 
                                                     
1. Congregation for the Doctrine of the Faith, Instruction on Respect for Human Life in Its Origin 
and on the Dignity of Procreation: Replies to Certain Questions of the Day, VATICAN (Feb. 22, 
1987), http://www.vatican.va/roman_curia/congregations/cfaith/documents/rc_con_cfaith_doc 
_19870222_respect-for-human-life_en.html [https://perma.cc/N73Y-YPS9]. 
2. See, e.g., Michele Goodwin, A View from the Cradle: Tort Law and the Private Regulation of 
Assisted Reproduction, 59 EMORY L.J. 1039, 1058–61 (2010) (discussing potential complications 
from ART). 
3. See June Carbone & Naomi Cahn, Embryo Fundamentalism, 18 WM. & MARY BILL RTS. J. 
1015 (2010). The tacit compromise underlying the development of assisted reproduction has been 
that “no laws are passed that even tangentially sanction embryo destruction and no laws are passed 
that intrude on the profitability of fertility treatments.” Id. at 1015; see also 1032–36. In addition, 
“[l]egislative and regulatory oversight of assisted reproduction has been characterized by moral 
posturing and regulatory gridlock.” Id. at 1032. 
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insurance coverage.
4
 
For most of its existence, therefore, ART practices have taken place in 
the context of a different consumer and ethical infrastructure than other 
health care services. This means that even where fertility clinics 
experience many of the same forces as the rest of the medical profession, 
the implications may not be the same. For example, ART practitioners, 
like other medical clinics, face pressures to innovate. This innovation 
increases returns to scale and take place in the context of global 
competition. In the fertility context, consolidation, at least initially, may 
offer more rather than less price competition and competition across 
jurisdictional lines offers not just opportunities to leverage price 
differences but to jurisdiction shop for different regulatory 
environments. Competition for providers across state and national lines 
may therefore give consumers a wider array of choices. 
At the same time, the competition for fertility services involves 
selection for particular services as much as, if not more, than selection 
for price. The global market for fertility services includes wealthy and 
sophisticated patients who may scour the world for a place willing to 
provide surrogacy services for older or non-traditional couples. It also 
includes those who would like to employ new techniques to select a 
child of a desired sex, to avoid the transmission of hereditary diseases, or 
to conceive a “savior sibling” capable of providing a bone marrow 
transplant to a family member whose life depends on finding a 
compatible donor.
5
 Increased competition and “fertility tourism” may 
thus expand the availability of services not just by making them more 
affordable, but also by making it easier to evade ethical restrictions that 
limit the availability of controversial services.
6
 
                                                     
4. Insurance Coverage in Your State, RESOLVE, http://www.resolve.org/family-building-
options/insurance_coverage/state-coverage.html [https://perma.cc/3TYH-CQNE] (last visited Feb. 
23, 2016) (noting that only fifteen states currently offer this coverage). 
5. See, e.g., Gender Selection, FERTILITY INSTS., http://www.fertility-docs.com/programs-and-
services/gender-selection/select-the-gender-of-your-baby-using-pgd.php?utm_expid=859852-
9.IPJ9NYcHRJCpZh9q8VY-vg.0&utm_referrer=https%3A%2F%2Fwww.google.com%2F 
[https://perma.cc/F8LU-5H46] (last visited Feb. 5, 2016) (providing sex selection as an advertised 
service). For a discussion of “savior siblings,” see MALCOLM K. SMITH, SAVIOUR SIBLINGS AND 
THE REGULATION OF ASSISTED REPRODUCTIVE TECHNOLOGY: HARM, ETHICS AND LAW 1–2 (2015) 
(defining the term and arguing for the use of “saviour children” rather than “saviour sibling” since 
the children chosen for such reasons are not necessarily limited to siblings); Susan M. Wolf et al., 
Using Preimplantation Genetic Diagnosis to Create a Stem Cell Donor: Issues, Guidelines & 
Limits, 31 J.L. MED. & ETHICS 327, 330–36, 336 n.5 (2003) (discussing the bioethics issues in 
“savior sibling” cases); I. Glenn Cohen, Intentional Diminishment, the Non-Identity Problem, and 
Legal Liability, 60 HASTINGS L.J. 347, 364 (2008) (discussing possible feelings of guilt by savior 
siblings who refuse to consent to use of their tissue). 
6. See Choosing a Medical Tourism Agency to Plan Your Fertility Treatment Abroad, FERTILITY 
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Faced with these clinic practices, infertile individuals become 
“consumers” as well as patients. Patients may enjoy a choice of clinics 
on the east and west coasts of the United States, as well as abroad.
7
 They 
can, and often do, ask exactly what fertility procedures will cost, and can 
consider different potential fertility packages in deciding on a course of 
action. Still, a larger percentage of the public may pursue less expensive 
options in Mexico than those who will price shop within their home 
markets in the United States, much less negotiate with individual 
providers. Some argue that any form of price consideration reduces one 
of life’s most fundamental experiences—the creation of a human life—
to a dollars-and-cents commercial transaction.
8
 Others express concern 
that for-profit clinics press the limits of ethical behavior in their desire to 
recruit more patients.
9
 Yet others hold up fertility clinics as a model of 
informed choice: the infertile at least enjoy a choice of clinics, with 
transparent prices, that allow the patients to select their preferred course 
of treatment.
10
 Discovering the true cost of cancer surgery is, in contrast, 
a much more difficult process.
11
 
This Article will assess the forces on the horizon remaking the 
fertility industry. In Part I, the Article discusses the differences between 
health care generally and ART services and the forces that produce these 
differences. In Part II, the Article identifies looming events remaking the 
nature of fertility services. These forces include the impact on ART 
services of greater consolidation in the health care industry, the 
prospects for expanding (or contracting) insurance coverage, the likely 
sources of funding for future innovation in the industry, and the impact 
of globalization and fertility tourism. The Article conducts this inquiry 
                                                     
TREATMENT ABROAD, http://fertility.treatmentabroad.com/agencies/choosing-a-medical-tourism-
agency [https://perma.cc/CE8Y-93H3] (last visited Feb. 5, 2016). 
7. See infra notes 54–55 (describing clinic efforts to increase geographic reach within the United 
States); infra notes 153–70 and accompanying text (describing growth of fertility tourism across 
international lines); DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE, AND POLITICS 
DRIVE THE COMMERCE OF CONCEPTION 54 tbl.2-1 (2006) (describing location of largest clinics, 
which tend to be concentrated in the East Coast, and major U.S. cities). 
8. ANTHONY OAKLEY DYSON, THE ETHICS OF IVF 35 (1995) (stating that “IVF involves the 
commodification, commercialization and exploitation of persons and processes”). 
9. See, e.g., Goodwin, supra note 2, at 1056 (suggesting that “aggressive fertility claims distort 
reproductive realities and misinform patients; ART’s failure rate is estimated to be 70%”). 
10. See Jody Lyneé Madeira, Conceiving of Products and the Products of Conception: Reflections 
on Commodification, Consumption, ART, and Abortion, 43 J.L. MED. & ETHICS 294, 299–300 
(2015) (summarizing the debate). 
11. See, e.g., STEVEN BRILL, AMERICA’S BITTER PILL: MONEY, POLITICS, BACKROOM DEALS, 
AND THE FIGHT TO FIX OUR BROKEN HEALTHCARE SYSTEM (2015) (documenting opaque billing 
practices in health care). 
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by examining the changing business model of the industry and 
recounting interviews with providers about the potential consequences of 
that change. 
In Part III, the Article concludes that future developments will likely 
remake the industry in fundamental ways. The United States, long a 
pioneer in fertility clinics, has taken a largely free market approach to 
innovation that stands in contrast with the development of other medical 
advances, which are far more likely to be the product of either 
substantial public funding or extensive government oversight. 
Innovation in the future is increasingly likely to occur either through 
private funding or abroad. In either event, the relationship between 
providers, patients, and regulatory authorities is likely to be more 
attenuated. Accordingly, the Article concludes that concentration in the 
American market, in contrast with other medical services, may not 
necessarily raise prices, and price differentiation may proceed more from 
fertility tourism than from competition within a single geographic 
region. The largest challenge may be linking those who would fund 
innovation, whether innovation that produces new high cost products or 
innovations making fertility services more accessible and affordable, 
with constantly shifting market niches of a globalized era. 
I. BABY MARKETS: THE BUSINESS OF FERTILITY 
Health care, of course, has long been a business. In some eras, it has 
been a service that could be separated into for-profit and not-for-profit 
sectors.
12
 That changed with the development of third-party payment 
systems.
13
 In 1940, ten percent of Americans had health insurance.
14
 By 
1957, that number increased to seventy-two percent, prompted primarily 
by the growth in employer-provided health insurance.
15
 The expansion 
of Medicare and Medicaid extended health care coverage to the elderly 
and the poor, who did not have or could not get other health care 
benefits.
16
 By 2013, the percentage of the American public not covered 
by any health insurance had dropped to fourteen percent.
17
 As a result, 
                                                     
12. See Terry L. Corbett, Healthcare Corporate Structure and the ACA: A Need for Mission 
Primacy Through a New Organizational Paradigm?, 12 IND. HEALTH L. REV. 103, 110 (2015) 
(discussing how non-profit hospitals once gave doctors greater freedom from market pressures). 
13. Id. at 121.  
14. Eleanor D. Kinney, For Profit Enterprise in Health Care: Can It Contribute to Health 
Reform?, 36 AM. J.L. & MED. 405, 409 (2010). 
15. Id. 
16. Id. at 409, 411–12. 
17. JESSICA C. SMITH & CARLA MEDALIA, U.S. CENSUS BUREAU, HEALTH INSURANCE 
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even medical providers with a mandate to cover underserved populations 
do not provide services without charge. Instead, they receive substantial 
revenues from third-party payers.
18
 Further, with third-party payers such 
as private insurance companies or state-run Medicare and Medicaid 
programs, the doctor may not necessarily be aware of the true cost of the 
treatment or the relationship between those costs and what patients pay 
directly.
19
 
The development of fertility treatments, in contrast, has taken place in 
relatively smaller clinics that rely to a much greater degree on customers 
who pay out-of-pocket.
20
 The portion of the population most likely to be 
concerned about fertility issues is also the least likely to have health 
insurance; those between the ages of eighteen and thirty-five—the peak 
childbearing years—are less likely than younger or older people to have 
health care coverage.
21
 Only fifteen states mandate any fertility 
coverage, and their mandates are neither comprehensive nor uniform.
22
 
                                                     
COVERAGE IN THE UNITED STATES: 2013, at 4 fig.4 (2014), 
https://www.census.gov/content/dam/Census/library/publications/2014/demo/p60-250.pdf 
[https://perma.cc/G4X7-WPG9]. 
18. See, e.g., Erin C. Fuse Brown, Irrational Hospital Pricing, 14 HOUS. J. HEALTH L. & POL’Y 
11, 37 (2014) (explaining charity care hospital billing practices). 
19. Id. at 16, 35 n.127 (noting that hospital prices remain almost completely opaque, variable 
even with the same hospital and unintelligible and involve both physician and hospital components). 
20. See Judith F. Daar, Accessing Reproductive Technologies: Invisible Barriers, Indelible 
Harms, 23 BERKELEY J. GENDER L. & JUST. 18, 37 (2008) (observing that insurance mandates have 
relatively little effect on fertility treatment usage because those with insurance coverage are the 
patients most likely to be able to afford fertility treatments on their own); Marianne Bitler & Lucie 
Schmidt, Health Disparities and Infertility: Impacts of State-Level Insurance Mandates, 85 
FERTILITY & STERILITY 858, 864 (2006). But see SPAR, supra note 7, at 33 (observing that there are 
still barriers to entry, given the lengthy training necessary to be able to do IVF, and returns to scale). 
21. SMITH & MEDALIA, supra note 17, at 6 fig.4. Racial disparities are also substantial, with the 
highest utilization among older, educated Caucasian women with income greater than 300 percent 
above the poverty level. Low-income women with under twelve years of education were the least 
likely to access infertility services. See Eve C. Feinberg et al., Comparison of Assisted Reproductive 
Technology Utilization and Outcomes Between Caucasian and African American Patients in an 
Equal-Access-to-Care Setting, 85 FERTILITY & STERILITY 888, 889 (2006). Yet, lower income and 
minority women experience higher rates of involuntary infertility. Daar, supra note 20, at 39 
(“Hispanic women, non-Hispanic black women, and other women of color are significantly more 
likely to be infertile than white women.”); see Kimberly M. Mutcherson, Transformative 
Reproduction, 16 J. GENDER RACE & JUST. 187, 222 (2013) (“[A] disproportionate number of 
infertile women in this country are Black.”). 
22. Seema Mohapatra, Fertility Preservation for Medical Reasons and Reproductive Justice, 30 
HARV. J. RACIAL & ETHNIC JUST. 193, 206 (2014); see also Tara Siegel Bernard, Insurance 
Coverage for Fertility Treatments Varies Widely, N.Y. TIMES (July 25, 2014), 
http://www.nytimes.com/2014/07/26/your-money/health-insurance/insurance-coverage-for-fertility-
treatments-varies-widely.html [https://perma.cc/Q72F-QLRL] (noting that of the states that mandate 
coverage, only eight—Arkansas, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, New 
Jersey and Rhode Island—require some level of coverage for IVF). 
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In the states that do not mandate coverage, insurance companies 
typically do not cover such treatments, thus utilization of fertility 
services falls.
23
 Public programs such as Medicaid similarly treat fertility 
issues as elective and uncovered, and private charities do not place much 
emphasis on access to services such as IVF.
24
 Deborah Spar estimates 
that only a little more than one-third of the infertile seek fertility 
treatments.
25
 
As a result, fertility treatments, much like cosmetic surgery or 
dentistry, traditionally took place in fragmented practices dependent on 
out-of-pocket patient payments.
26
 This is changing, however, as clinics 
consolidate to take advantage of economies of scale. These clinics treat 
patients who are socioeconomically advantaged
27
 and, with fewer third-
party imposed requirements, they may be quite profitable.
28
 Still, they 
depend on the patients’ ability and willingness to pay. 
The United States provides relatively little regulation of fertility 
treatments.
29
 Federally mandated reporting requirements, which include 
                                                     
23. See Melinda B. Henne & M. Kate Bundorf, Insurance Mandates and Trends in Infertility 
Treatments, 89 FERTILITY & STERILITY 66 (2008) (noting that comprehensive insurance mandates 
are associated with greater utilization of ART and lower rates of births per cycle and multiple births 
per ART birth); John A. Robertson, Commerce and Regulation in the Assisted Reproduction 
Industry, 85 TEX. L. REV. 665, 674 (2007) (reviewing SPAR, supra note 7, and discussing the 
limited availability of insurance coverage for assisted reproduction). 
24. Mohapatra, supra note 22, at 223. 
25. SPAR, supra note 7, at 32. 
26. See, e.g., Kimberly D. Krawiec, Altruism and Intermediation in the Market for Babies, 66 
WASH. & LEE L. REV. 203, 213–14 (2009) (“[P]rofits are undeniably a—if not the—motivating 
factor in the industry as well. Although many fertility centers are affiliated with nonprofit hospitals 
or academic institutions, the fertility center itself is often a professionally managed, for-profit, 
private corporation.” (emphasis in original)); HARRIS WILLIAMS & CO., FERTILITY MARKET 
OVERVIEW (2015) [hereinafter FERTILITY MARKET OVERVIEW], http://www.harriswilliams.com/ 
sites/default/files/content/fertility_industry_overview_-_2015.05.19_v10.pdf 
[https://perma.cc/WA9W-2FGN] (commenting on highly fragmented nature of the U.S. market). 
27. Patients with higher incomes tend not just to be better able to pay for fertility treatments on 
their own; they are also more likely to have health insurance, and to have insurance that covers 
fertility treatments. On health insurance coverage, see SMITH & MEDALIA, supra note 17, at 9 tbl.4. 
28. See, e.g., Debora Spar & Anna M. Harrington, Building a Better Baby Business, 10 MINN. J.L. 
SCI. & TECH. 41, 49 (2009) (“ART has become a big business in the United States precisely because 
it costs so much.”). Spar and Harrington estimate the cost per live birth (using a fifty-one percent 
success rate) at between $29,411 and $49,020. Id. at 50. 
29. Judith Daar emphasizes that this perception of American practices comes from the lack of a 
“top-down” system in the United States, but that the notion that American fertility clinics are the 
wild west of medicine is an “urban myth.” Judith Daar, Federalizing Embryo Transfers: Taming the 
Wild West of Reproductive Medicine?, 23 COLUM. J. GENDER & L. 257, 257, 266 (2012). She 
emphasizes instead that American reproductive practice, like all others areas of medicine, “is subject 
to quality control through a variety of mechanisms, most notably licensure of physicians by state-
based medical boards, application of practice standards established by professional societies, and 
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reports of success rates, constitute the most direct regulation.
30
 Perhaps 
as importantly, the lack of federal research support also influences 
industry practices.
31
 Even when there is no direct public oversight of 
medical practices, federal grants often prompt medical innovations 
through research funds typically conditioned on agreement to observe 
ethical practices prescribed by professional groups or committees.
32
 
Congress, however, has restricted research on embryos since the 1970s, 
starting almost immediately after the legalization of abortion. These 
efforts culminated in the “Dickey Amendment,” which has been attached 
to every Health and Human Services appropriations bill since 1996.
33
 
The amendment forbids federal funding for “research in which a human 
embryo or embryos are destroyed, discarded, or knowingly subjected to 
risk of injury or death.”34 Fertility clinics therefore rely either on private 
research funding, with relatively few restrictions compared to federal 
grants,
35
 or their patients’ willingness to undergo certain untested IVF 
                                                     
private tort litigation.” Id. at 262. These physician-based regulatory systems, however, tend to be 
voluntary rather than mandatory, suggesting professional guidelines without necessarily prohibiting 
alternative practices. In addition, enforcement, if it occurs at all, typically occurs after harm has 
occurred. In the case of “Octomom” Nadya Suleman, for example, her doctor violated professional 
guidelines in implanting a large number of embryos, and ultimately lost his medical license because 
of it. Id. at 313–14. Yet, no regulation controls the acceptable number of embryos that can be 
implanted at one time, and the after-the-fact-actions taken against the doctor involved almost 
certainly reflect the publicity the case generated, and the utterly irresponsible nature of the doctor’s 
actions. Id. at 314 (noting that the doctor’s appeal was rejected because of the “serious breach of the 
standard of care”). 
30. Id. at 267–68 (discussing comprehensive reporting requirements); see also Fertility Clinic 
Success Rate and Certification Act, 42 U.S.C. § 263(a)(l)–(7) (2012). Federal regulations also cover 
laboratory testing. See Clinical Laboratory Improvement Act of 1988, 42 U.S.C. § 263(a); 21 C.F.R. 
§§ 1271.55, 1271.80 (2016) (implementing regulations). 
31. See Carbone & Cahn, supra note 3, at 1052. In contrast, the federal government had once 
funded the vast majority of biomedical research. See June Carbone, Toward a More Communitarian 
Future? Fukuyama as the Fundamentalist Secular Humanist, 101 MICH. L. REV. 1906, 1923 (2003). 
32. See Note, Guiding Regulatory Reform in Reproduction and Genetics, 120 HARV. L. REV. 574, 
579 (2006).  
33. Carbone & Cahn, supra note 3, at 1033–34. 
34. Balanced Budget Downpayment Act, Pub. L. No. 104-99, § 128, 110 Stat. 26, 128 (1996). 
The 2005 version of the amendment provided:  
None of the funds made available in this Act may be used for . . . research in which a human 
embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death 
greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b) and section 
498(b) of the Public Health Service Act (42 U.S.C. 289g(b)).  
Department of Health and Human Services Appropriations Act, 2006, Pub. L. No. 109-149, § 509, 
119 Stat. 2833, 2880 (2005). 
35. Note, supra note 32, at 586–87 (observing that IVF clinics had little difficulty attracting 
private research funds, and in this context, “caution was not a foremost concern, and few external 
forces existed to slow the work of the clinic”). 
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procedures such as using genetic material from three individuals without 
clinical trials beforehand.
36
 
Despite the lack of public research support, the combination of private 
support, lack of restrictions, and paying patients has allowed the United 
States to develop a large, profitable fertility industry—one whose 
potential impact is likely to grow.
37
 
II. REMAKING BABY-MAKING 
Newsweek ran a piece a number of years ago, before the end of 
the cold war, that recited a little ditty attempting to explain 
differences in national political cultures. It went something like 
this: in the United States, everything is allowed unless it is 
specifically prohibited; in East Germany, everything is 
prohibited unless it is specifically allowed; in the Soviet Union, 
everything is prohibited especially if it is allowed; and in Italy, 
everything is allowed especially if it is prohibited. While casual 
and perhaps too cute, this ditty nonetheless captures some 
fundamental approaches to governance. The NBAC [President 
Clinton’s National Bioethics Advisory Commission] took this 
advice to heart.
38
 
A decade and a half ago, Alto Charo’s ditty summarized the state of 
the fertility business. National cultures—public and private—determined 
the approaches to fertility treatments, and in the United States, public 
bodies mostly looked the other way, allowing private entities to oversee 
the development of the industry largely on their own. To be sure, the 
occasional front page news story, from Baby M
39
 to Octomom,
40
 focused 
the spotlight on fertility practices and led to narrowly focused reforms, 
                                                     
36. See Carbone, supra note 31, at 1920–21 (attributing lack of animal testing to lack of research 
funding); infra Section II.C (describing the cytoplasmic research that occurred at St. Barnabas in 
1996). The Food and Drug Administration, however, has since asserted jurisdiction over such 
procedures, with the result that such direct testing on patients has become more likely to take place 
abroad. See infra note 104 and accompanying text. 
37. See generally SPAR, supra note 7 (arguing that it is necessary to acknowledge the commercial 
implications of fertility treatment and its market dynamics). 
38. R. Alta Charo, Cloning: Ethics and Public Policy, 27 HOFSTRA L. REV. 503, 508 (1999). 
39. See In re Baby M., 537 A.2d 1227 (N.J. 1988) (invalidating surrogate parenting arrangements 
for violating state law, enacted long before the practice of surrogacy was known in the state, 
prohibiting the payment of money in connection with adoption). 
40. See, e.g., Naomi R. Cahn & Jennifer M. Collins, Eight Is Enough, 103 NW. U. L. REV. 
COLLOQUY 501, 501 (2009) (critiquing IVF practices that led to the birth of octuplets and proposing 
limits on the number of embryos to be implanted at any one time). 
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but no comprehensive oversight of the industry emerged.
41
  Nonetheless, 
new factors may prompt reconsideration; this Part examines these factors 
in turn. Section II.A considers the changing nature of health care more 
generally as new technologies and regulations bring increasing returns to 
scale. Section II.B then examines how increased demand for fertility 
services and the growing evidence that links reproductive efforts and 
children’s health to adult genetic predispositions is increasing the 
demand for insurance coverage. Section II.C considers the cumulative 
effect of narrowly focused regulations on the climate for innovation, as 
the combination of federal limits and state restrictions affect 
developments on the horizon. Finally, Section II.D. addresses how the 
globalization of the supply of fertility services and customer demand 
make the relevant markets for fertility services increasingly international 
in scope. 
A. The Changing Health Care Landscape 
Consolidation increasingly characterizes the health care landscape, 
with individual physicians selling practices to larger entities,
42
 hospital 
associations becoming larger, and insurance companies merging.
43
 These 
trends began in the 1990s,
44
 accelerated with a shift in Medicare 
reimbursement formulas,
45
 and increased further after adoption of the 
Affordable Care Act (ACA) in 2009.
46
 Some of the reasons for these 
                                                     
41. Indeed, as Charo notes, some bodies such as the NBAC, which were set up to consider 
oversight, did not enact reforms. Charo, supra note 38. In Georgia, which took up legislation 
designed to curb fertility practices, the only result was state authorization of embryo adoption 
procedures, but not limitations on the fertility industry. Cahn & Collins, supra note 40, at 508; see 
also Carbone & Cahn, supra note 3, at 1041–43 (recounting Georgia’s efforts to place limits on 
embryo implantation after 100,000 people contacted the state legislature opposing the measure). 
42. See Lucia DiVenere, The Affordable Care Act and the Drive for Electronic Health Records: 
Are Small Practices Being Squeezed?, 25 PRAC. MGMT. 36, 36 (2013), 
http://www.jfponline.com/fileadmin/qhi/obg/pdfs/0713_PDFs/0713_OBG_DiVenere.pdf 
[https://perma.cc/RQX2-2GLR] (“In 2000, 57% of all physicians were in independent practice; by 
the end of 2013, only 36% of physicians are projected to remain independent.”). 
43. See, e.g., Thomas F. Cotter, Patents, Antitrust, and the High Cost of Health Care, ANTITRUST 
SOURCE, Apr. 2014, at 1, 5 (“[T]he market for health care related services has become remarkably 
more concentrated over the past two decades.”); Brandon Gould, How the Countervailing Power of 
Insurers Can Resolve the Tradeoff Between Market Power and Health Care Integration in 
Accountable Care Organizations, 22 GEO. MASON L. REV. 159, 178 (2014). 
44. Cotter, supra note 43, at 5. 
45. Gould, supra note 43, at 167 (noting the origination of some of the pressures for consolidation 
with creation of accountable care organizations, first implemented as part of Medicare 
reimbursement reforms). 
46. See 5 Forces Driving Hospital Consolidation, STRATASAN (July 10, 2013), 
http://stratasan.com/5-forces-driving-hospital-consolidation/ [https://perma.cc/7BTA-ZNEA] 
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trends will have little if any impact on reproductive care. For example, 
the change in Medicare reimbursement formulas to emphasize outcome-
oriented health care is likely to have little effect on fertility services.
47
 
Nonetheless, other industry trends may affect fertility clinics as well. 
First, even if everything else were to stay the same, one of the factors 
driving consolidation is the increased costs associated with the switch to 
electronic records. Industry observers note that “the healthcare sector’s 
reliance on increasingly sophisticated electronic medical records and 
other health information technologies to reduce costs and enhance 
quality, safety, and efficiency are foundational to healthcare reform.”48 
Yet, moving from a paper-based to an electronic system is expensive. 
The average cost of an electronic medical records system is $50,000 per 
physician,
49
 and implementing such a system requires training, 
maintenance, and compliance with various privacy laws and regulatory 
requirements that generate additional costs.
50
 The need to acquire and 
maintain these systems creates returns to scale that encourage larger 
practices or cost-sharing administrative groups. In itself, the switch to 
electronic records may be a problem of transition; over time, it may 
interact with other changes to encourage consolidation of a fragmented 
industry. 
Fertility clinics face further pressures to consolidate because of the 
returns to scale within the industry. Deborah Spar reports that smaller, 
private clinics have faced increased pressure to join networks such as 
IntegraMed, which provides member clinics with “management advice, 
pharmaceutical products, and in house-financing.”51 These networks may 
be better able to negotiate with drug companies for volume discounts,
52
 
they can ease the problems associated with financing new equipment and 
lab maintenance in a rapidly changing field, and they offer advantages in 
                                                     
(showing an increase in mergers post-2009). 
47. Gould, supra note 43, at 178 (“Reliance on Medicare data may also be inappropriate for 
services infrequently provided to Medicare beneficiaries, such as pediatric and obstetric care.”). 
48. Brian Kerby, The Top Five Drivers of Healthcare Consolidation in 2015, CROW HORWATH 
(Apr. 21, 2015), http://www.crowehorwath.com/insights/healthcare-connection/top-five-drivers-hc-
consolidation-2015.aspx [https://perma.cc/AS5K-CEQE]. 
49. Paul R. Brezina et al., How Obamacare Will Impact Reproductive Health, 31 SEMINARS 
REPROD. MED. 189, 194 (2013). 
50. Id. 
51. SPAR, supra note 7, at 51.  
52. An industry analyst reports that the U.S. fertility services market of about $3 to $4 billion 
consists of $1.7 to $2.5 billion in fertility services and approximately $1.5 billion for fertility 
medications. See FERTILITY MARKET OVERVIEW, supra note 26, at 1. 
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advertising and new patient acquisition.
53
 As a result, fertility clinics, 
like the rest of the health care field, are experiencing increasing 
consolidation.
54
 The result does not just increase clinic size; it also 
expands clinic geographic reach.
55
 
Interviews with fertility industry professionals underscore the 
accuracy of Spar’s assertions, though the doctors’ impressions (and 
business knowledge and savvy) vary considerably. One physician 
remarked: 
[W]hen you talk to physicians in our field . . . there’s a strong 
sense that consolidation is occurring, and the forces that are 
driving us . . . [are] to be able to have electronic medical records, 
being able to have the embryology resources and technology, 
and all the other back office, IT and marketing and all the types 
of things you need today to . . . compete. It’s hard to do as a solo 
practice.
56
 
An executive with a for-profit fertility clinic management corporation 
stressed the importance of “efficiencies of scale”: “[g]roup purchasing is 
a big one. The cost of equipment. If that’s done through group 
purchasing arrangement[s], they can get really good discounts through a 
larger organization. . . . Or also, the financial advantages if they want to 
expand—it’s very expensive to build out a practice.”57 Finally, 
consolidation may improve research, which may be particularly 
important for university centers: in a large group, “[b]ecause the EMR 
[Electronic Medical Records] is linked to all these practices, they have a 
massive database. So they can actually provide fantastic data for any 
form of research that’s being done within the organization. So they get 
recognition—academic recognition—as much as clinical recognition.”58 
Doctors also perceive that consolidation may be a response to tough 
                                                     
53. SPAR, supra note 7, at 51 (describing a doctor who joined his practice to IntegraMed reporting 
that it allowed him to keep his practice open “52 weeks a year, fully staffed all the time, offering 
even the most exotic reproductive technologies”). 
54. FERTILITY MARKET OVERVIEW, supra note 26, at 9 (noting that small industry players want 
to broaden their access to patients and that referral networks and platform providers like Integra 
seek affiliation with additional practices to spur growth, realize synergies, and increase geographic 
presence). 
55. Id. 
56. Telephone Interview by Jody Lyneé Madeira with Anonymous Physician Two (Aug. 15, 
2015) (on file with author) [hereinafter Interview with Physician Two]. 
57. Telephone Interview by Jody Lyneé Madeira with Anonymous Fertility Clinic Management 
Corporation Executive (Aug. 29, 2015) (on file with author) [hereinafter Interview with 
Management Corporation Executive]. 
58. Id. 
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market conditions. An executive in a for-profit fertility clinic 
management corporation described these changing dynamics: “I think 
it’s very difficult for a single physician, or even [a] two physician 
practice, to survive because of the changing demographic. A lot of the 
population is getting older. . . . It’s very difficult for them in the current 
[climate], especially with insurance issues.”59 An official with a fertility-
related nonprofit explained the logic behind consolidation: 
[Y]ou have a lot of people who can’t access it, so the field isn’t 
growing. And so you’ve got . . . to figure out how you’re gonna 
keep sustaining. So a lot of times, that’s consolidation. That’s 
[saying], “Look the guy across the stress is struggling too, or 
maybe not so much struggling, but we’re all sort of status quo; 
maybe if we join forces, we’ll be more efficient, we’ll capture 
more of the . . . patient population, and we’ll be in a position to 
continue as an entity, to grow and improve.”60 
There is much speculation that the ACA, in particular, will prompt 
further consolidation.
61
 As an executive at a for-profit fertility 
pharmaceutical corporation stated: 
[I]t’s kind of analogous on some level to what we’ve seen in the 
hospitals in the [1980s] where . . . the small regional hospitals 
were kind of consolidating to form . . . bigger, more 
geographically dispersed conglomerates. . . . [Everyone’s going 
to] speculate that okay, we have the Affordable Care Act 
looming in 2016, most states won’t be able to afford to include 
fertility in their essential health benefits package. And that’s 
gonna . . . repeal, or lessen the effects of these mandates 
and . . . the whole market’s going to drop back from a heavily 
managed market to probably more of a cash market, which will 
shrink the market significantly. . . . These practices are realizing 
that to be competitive in this space, and potentially be 
competitive in the next five to ten years . . . that they’re going to 
have to figure out how to do this more effectively, cost-
effectively. And consolidation seems to be the approach. . . . A 
lot of the practices that are doing this are already the largest 
                                                     
59. Id. 
60. Telephone Interview by Jody Lyneé Madeira with Anonymous Non-Profit Official (Aug. 28, 
2015) (on file with author) [hereinafter Interview with Non-Profit Official]. 
61. The ACA requires the U.S. Department of Health and Human Services (HHS) to establish a 
minimum level of health benefits that must be offered by certain health plans that are participating 
in the individual and small group health insurance markets. HHS could chose to include fertility care 
as a benefit within the maternity care category, but it has not yet made a decision on the issue. See 
Daar, supra note 29, at 322. 
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practices in their region. And . . . now they’re just moving out 
and gobbling up their local competition, . . . realizing they just 
can’t compete with the economies of scale working against 
them.
62
 
The trend toward consolidation in the fertility industry may be unique 
in some respects. This physician felt that consolidation patterns in 
fertility medicine were different than in other fields of medical practice: 
I don’t think we feel the pressures as much as in other 
fields. . . . I know there are hospitals gobbling up practices, 
particularly primary care-type practices, [and that] hasn’t 
touched us yet. . . . [M]ost IVF centers don’t want to be 
restricted, . . . and beholden to a hospital system, so the few that 
are still in them . . . often look at ways of getting out of there.
63
 
A top official in a nonprofit fertility organization noted that, not only 
is there a trend toward consolidation, but practices in one state are 
beginning to expand outside their current regions and other clinics in the 
same region may merge: 
I think what we’ve seen . . . in the last couple of years are larger 
clinics—so they might be top ten or top fifteen in the U.S. in 
terms of number of IVF cycles—that are expanding outside their 
original states, into other states. So you see this with clinics such 
as Shady Grove Fertility going to Pennsylvania. You’ll see 
clinics like Boston IVF opening offices in New York, like 
Albany, and . . . Colorado Center for Reproductive Medicine, or 
CCRM, . . . opening an office in Houston, Texas. . . . [T]he other 
thing is . . . clinics in the same marketplaces that are either 
merging [or] consolidating. . . . [Y]ou saw the announcement 
that RMA of New Jersey, which is one of the largest clinics in 
the country, is forming a “partnership” with . . . Shady Grove 
Fertility.
64
 
Some may have concerns that consolidation could negatively impact 
patients’ care experience. One physician opined, “customer experience is 
a number one issue and they don’t want to feel like cattle or like [a] 
number, like they usually feel when they’re in these big centers where 
they have . . . three, four thousand cycles a year.”65 Another physician 
                                                     
62. Telephone Interview by Jody Lyneé Madeira with Anonymous Pharmaceutical Corporation 
Executive (Sept. 11, 2015) (on file with author) [hereinafter Interview with Pharmaceutical 
Corporation Executive]. 
63. Interview with Physician Two, supra note 56. 
64. Interview with Non-Profit Official, supra note 60. 
65. Telephone Interview by Jody Lyneé Madeira with Anonymous Physician One (Aug. 13, 
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stressed, “I wouldn’t want to imply that the choice is between a small, 
wonderful practice, or a big, . . . unfeeling conglomerate.”66 That 
physician did believe, however, that larger practices could focus more 
intensely on creating a personalized patient experience: 
I think we’re very big. . . . Every patient at our practice has one 
physician and one nurse and a home office[,] and I think we’ve 
worked really hard to avoid that perception, or that 
experience. . . . And we give patient surveys quarterly, and we 
[give] our staff a bonus for patient satisfaction. All these things 
are critical to us. So I think a smart, big consolidated group will 
recognize how critical patient care and patient experience is, and 
will probably do better. . . . I think that big practices have the 
ability to look at the data, and the desire to[,] and the resources 
to ensure best practices, . . . high quality technology, and the 
embryology lab in particular, so I think there’s an advantage.67 
Interestingly, this physician also objected to the use of “conglomerate” 
versus “consolidation”: “[conglomerate] has such negative 
implications. . . . [I]t implies impersonal, profit-driven, without any 
thought for quality of patient care.”68 The official in a fertility-related 
nonprofit agreed: “however they set up their teams, [the large practices 
have] been able to do it in such a way that patients still feel an incredible 
connection to that practice.”69 
Finally, consolidation can promote best practices. According to 
Physician One, “we physicians, . . . we’re not good 
collaborators, . . . especially the [baby] boom generation.”70 If this is 
true, consolidation helps to break down barriers to collaboration: 
IntegraMed, for instance, has an annual conference in which 
[best practices] are shared . . . and they’re looking at outcomes 
and . . . encouraging practices to share best practices, and when 
you’re part of the network, you’re much more transparent with 
each other, without the posturing that you would have with a 
typical large ASRM meeting.
71
 
The official in a fertility-related nonprofit organization stressed that 
consolidation enables the latest technologies to spread from practice to 
                                                     
2015) (on file with author) [hereinafter Interview with Physician One]. 
66. Interview with Physician Two, supra note 56. 
67. Id. 
68. Id. 
69. Interview with Non-Profit Official, supra note 60. 
70. Interview with Physician One, supra note 65. 
71. Interview with Physician Two, supra note 56. 
05 - Carbone Madeira.docx (Do Not Delete) 3/23/2016  4:28 PM 
86 WASHINGTON LAW REVIEW [Vol. 91:71 
 
practice: 
RMA of New Jersey . . . they’ve really developed this 
chromosomal screening . . . . that technology is [now being 
used] in many practices, so it’s sort of like leveling the playing 
field . . . [T]hat’s a technology that is still proprietary to RMA of 
New Jersey, but they’re . . . partnering with other clinics to offer 
that.
72
 
The official also noted that larger firms tended to “have more ability 
to offer financing programs” and that biotech firms developing new 
technologies were “going to the large practices to do their testing, and 
the larger practices seem to be more open to being early adopters.”73 
While these doctors differ in their attribution of cause and effect, and 
they differ significantly in their knowledge of and ability to assess 
business trends, they tend to agree that consolidation is an increasing 
characteristic of the fertility industry, and that the consolidation trend is 
likely to continue. Deborah Spar concludes that the most successful 
clinics “are either very high volume or very high tech,” and the need to 
compete in such an arena is squeezing the profit margins of the “smaller, 
less sophisticated, less commercial” clinics, increasing the pressure to 
merge.
74
 Doctors’ sense that continuing market pressure produces greater 
consolidation is almost certainly accurate. 
B. Expanding Insurance Coverage 
A potentially sweeping effect on the structure of the fertility market is 
the possibility of greater insurance coverage. Spar describes insurance 
coverage as a double-edged sword for the fertility industry: 
On the one hand, when insurers cover infertility as a medical 
illness, they nearly guarantee a greater demand for fertility 
treatments: people who previously couldn’t afford treatment 
suddenly enter the market, and people who bought minimal 
services now buy more. Thus, political demands in this industry 
can easily translate into expanded commercial demand. On the 
other hand, though, insurance coverage comes at a cost, forcing 
providers to charge only what the insurers will pay. 
Accordingly, insurance—and even the threat of insurance—acts 
to cap prices in the industry and put an even greater premium on 
                                                     
72. Interview with Non-Profit Official, supra note 60. 
73. Id. 
74. SPAR, supra note 7, at 58. 
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volume.
75
 
Spar’s analysis follows from the relative lack of price competition for 
IVF, which creates greater incentives for clinics to try to enter the upper 
end of the market rather than to expand volume through lower prices.
76
 
Ironically, while fertility clinic pricing is more transparent than pricing 
in forms of medicine covered by third-party payers, clinic prices tend to 
be relatively uniform across clinics, and customers tend not to 
comparison shop on the basis of price, at least within a given regional 
market.
77
 Insurance companies, in contrast, are repeat players with more 
information and greater market power, giving them greater ability than 
consumers to negotiate lower prices.
78
 
Doctors believe that the fact that most patients pay all or most of their 
IVF treatment costs already has made IVF more cost-effective than other 
forms of medical care that are subsidized by insurance. Physician Two 
observed the following: 
[W]hen a high percentage of patients pay out-of-pocket, you 
have to really focus on being transparent and competitive about 
pricing. And that, I think, is good for patients in this field. I 
think that fertility treatment is expensive, but actually if you 
compare it to “What is my IVF cycle cost versus an arthroscopy 
of the knee?” I think IVF is much more technically challenging 
and cost-effective and complex, and the time spent by people is 
much greater, but yet the arthroscopy probably gets twice as 
much, because of hospitals and surgery centers and the 
equipment manufacturers and everything else. . . . [F]ertility 
treatment’s price rises ha[ve] been less than medicine by a long, 
long way because of the transparency and the fact that patients 
are self-paying.
79
 
Yet, as Spar indicates, while the lack of third-party payment has 
restricted the size of the market, it has increased emphasis on high profit 
procedures rather than lower cost, higher volume approaches.
80
 
Expanded insurance coverage would change this dynamic, and could 
thus have a major impact on future industry development. So, however, 
could cutbacks in existing insurance coverage, which would have the 
                                                     
75. Id. at 34 (emphasis in original). 
76. Id. at 65. 
77. Id. at 59 (listing prices). 
78. Id. at 58. 
79. Interview with Physician Two, supra note 56. 
80. Spar describes clinics as competing to serve wealthy clients, with relatively high value, high 
profit services, rather than expanding volume. SPAR, supra note 7, at 34. 
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most effect in places like Massachusetts that now mandate broader 
insurance coverage.
81
 
Recent interviews with reproductive industry professionals suggest 
that the ACA provides no incentives for retaining insurance mandates 
compelling fertility services coverage, and speak to the dramatic changes 
in store should those mandates terminate in 2016. As one physician 
remarked: 
[T]here has to be a basic package, a basic basket of services that 
are offered. . . . So IVF would not be in a basic basket of 
services. So that may be the basis by which the state would then 
say, “Well hang on, if the basic medical package doesn’t include 
IVF, then it shouldn’t be a state mandate for IVF” . . . . I think 
the field . . . is anxious about . . . what the implications will 
be. . . . Nobody really knows what it means. . . . There’s a big 
school of thought that the mandates will disappear . . . I know 
we didn’t sign an expensive lease on a new space because we 
were worried . . . .
82
 
Insurance coverage need not extend to every aspect of IVF or other 
fertility treatments to have an effect. Current fertility-related medical 
coverage has three components: (1) diagnosis and treatment of 
underlying disorders that contribute to infertility such as endometriosis 
and surgery to correct it; (2) procedures designed to produce a pregnancy 
such as in IVF; and (3) medical care for pregnant women, and care of the 
resulting children.
83
 Insurance routinely covers costs associated with the 
first and third, but not treatments such as IVF aimed at fertility per se.
84
 
In addition, some prospective patients who would like access to IVF may 
have no known disorders,
85
 and with increasing numbers of same-sex 
couples having children with third-party participants, some of the 
demand for assisted reproduction does not involve medical infertility at 
                                                     
81. See MASS. GEN. LAWS ANN. ch. 175, §§ 1–227 (West, Westlaw through 2015 1st Annual 
Sess.); 211 MASS. CODE REGS. 37 (2016). 
82. Interview with Physician Two, supra note 56. 
83. See, e.g., Michael H. Shapiro, What Should Insurance Insure in the PPACA Age? On Paying 
for Other People’s Reproductive Decisions and Ambitions, 33 WHITTIER L. REV. 27, 29 (2011) 
(noting that health care insurance is certainly expected to cover medical disorders and pregnancy-
related illnesses and expenses). 
84. Insurers have argued that, while improper function of reproductive organs may be an illness, 
infertility is not. See Noah Baron & Jennifer Bazzell, Assisted Reproductive Technologies, 15 GEO. 
J. GENDER & L. 57, 78 (2014). 
85. FERTILITY MARKET OVERVIEW, supra note 26, at 2, put the percentage of “unexplained” 
infertility at twelve percent.  
05 - Carbone Madeira.docx (Do Not Delete) 3/23/2016  4:28 PM 
2016] BUYERS IN THE BABY MARKET 89 
 
all.
86
 
Industry professionals are well aware of the problems resulting from a 
lack of insurance coverage for infertility; as one physician stated, “from 
[one] hundred patients that require in vitro fertilization as a 
treatment . . . only ten to twenty are getting it in the States.”87 Another 
physician was frustrated by the lack of insurance for fertility issues as 
opposed to other procedures: 
My 84-year-old mother who is pretty healthy . . . just had a 
femoral artery dilated and angioplasty. And she’s on Medicare, 
and . . . she really probably did not need this procedure. . . . [I]t 
drives me crazy that Medicare will probably spend $30,000 or 
$40,000 on what she’s just been through, she didn’t really need, 
and yet I’ve had a 30-year-old woman with tubal factor 
infertility who could easily have two children but she can’t 
afford the $10,000 for the IVF cycle.
88
 
Thus, the scope of insurance may be changing, though in which 
direction is not yet clear. As knowledge about infertility increases, more 
medical causes may become apparent, and treatment of the underlying 
issues may be integrated with fertility care. For example, obesity 
increases the incidence of infertility and fertility-related obesity 
interventions can range from nutritional coaching to hormonal or other 
drug interventions to IVF.
89
 Greater integration of the two, such as 
requiring a weight-loss regimen before attempting IVF, may blur the 
distinctions between fertility and non-fertility medical procedures.
90
 
The most intriguing development along these lines involves the effect 
of increased genomic information as more couples become aware of 
hereditary conditions that could seriously impair the health of their 
offspring and could be eliminated through use of IVF and genetic 
screening.
91
 The result could increase the demand for IVF and increase 
                                                     
86. Scholars refer to this as “structural infertility” and explain that it “occurs when an individual 
or couple desires to reproduce but must do so through means other than sexual intercourse because 
of the social structure in which they self-identify. Single individuals and same-sex couples provide 
examples of structural infertility.” Daar, supra note 20, at 24. 
87. Interview with Physician One, supra note 65. 
88. Interview with Physician Two, supra note 56. 
89. See Renato Pasquali et al., Obesity and Infertility, 14 CURRENT OPINION ENDOCRINOLOGY 
DIABETES & OBESITY 482, 482–84 (2007) (describing the complex role of obesity in infertility and 
pregnancy outcomes). 
90. See FERTILITY MARKET OVERVIEW, supra note 26, at 6 (describing potential responses to 
obesity in intended parents). 
91. See David Sable, The Seven Trends that Define the Future of IVF, FORBES (Feb. 28, 2015, 
4:53 PM), http://www.forbes.com/sites/davidsable/2015/02/28/the-seven-trends-that-define-the-
future-of-ivf/. 
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the pressure for insurance coverage of both the genetic screening and the 
availability of IVF for those facing a significant possibility of passing on 
disabling traits.
92
 
Even without government mandates, health insurers, who will bear 
the costs for children with medical complications or special needs, have 
shown some inclination to expand coverage to include procedures that 
reduce overall costs. These procedures may extend to genetic screening 
as the ability to identify genetic risks increases, and may include at least 
some rounds of IVF as studies show that insurance coverage contributes 
to patient willingness to implant one embryo at a time, reducing the risks 
(and costs) associated with multiples.
93
 
The biggest unknown in this process, however, is how politics will 
affect the ART industry. On the one hand, interest in offering insurance 
coverage for fertility services is increasing as more couples delay 
childbirth and face potential difficulties having children.
94
 This may 
increase pressure on legislators to mandate coverage and on employers 
to include IVF coverage options.
95
 On the other hand, if insurance costs 
were to rise generally, employers might find IVF coverage a relatively 
easy benefit to drop. Moreover, both factors may occur simultaneously, 
with coverage (and coverage mandates) increasing more rapidly in large 
urban areas and better educated tech centers where the age of first birth 
is rising more rapidly, and coverage remaining limited in other parts of 
the country.
96
 
At present, insurance coverage for fertility services appears to be 
rising gradually. A 2013 study indicated that sixty-five percent of 
                                                     
92. Judith Daar observes that the Affordable Care Act gives HHS the authority “to specify which 
services and benefits are to be included within a benefit category as an essential health benefit. 
Fertility care, for example, could be included as a benefit within the maternity care category.” Daar, 
supra note 29, at 322. 
93. See id. at 315–19, 323 (noting that patients in the U.S. and abroad who have access to some 
form of insurance coverage for IVF deliver fewer multiples).  
94. Bernard, supra note 22. 
95. See Daar, supra note 29, at 321 (describing support for increased insurance coverage). 
96. In addition, the pressure for employers to extend coverage may vary considerably. See Matt 
McCue, OvaScience CEO Talks Apple, Facebook and the $9 Billion Fertility Market, FORTUNE 
(Oct. 16, 2014, 11:54 AM), http://fortune.com/2014/10/16/fertility/ [https://perma.cc/7H7G-62FJ] 
(“There is a trend in companies covering more fertility-related costs for employees; however, in the 
U.S. it varies greatly by employer and state.”). For a discussion of the role of religious objections to 
IVF in the failure to extend insurance coverage, see generally Carbone & Cahn, supra note 3. Where 
anti-abortion restrictions, such as personhood amendments, are seen as restricting IVF, however, 
those restrictions have lost at the polls, even in states such as Mississippi. See Jonathan F. Will, 
Beyond Abortion: Why the Personhood Movement Implicates Reproductive Choice, 39 AM. J.L. & 
MED. 573, 585 (2013).  
05 - Carbone Madeira.docx (Do Not Delete) 3/23/2016  4:28 PM 
2016] BUYERS IN THE BABY MARKET 91 
 
businesses with more than 500 employees will pay for an initial 
evaluation by a fertility specialist, though only twenty-seven percent 
cover IVF (up from twenty-three percent in 2012). Forty-one percent of 
large employers cover drug therapies associated with infertility 
treatments.
97
 
And what about IVF costs for patients paying out-of-pocket—will 
average prices for an IVF cycle trend upward or downward, or stay the 
same? The long-term stability of the average cost of an IVF cycle might 
actually mean that costs have decreased over time, however expensive it 
may seem in today’s dollars. As Physician One emphasized, “they have 
decreased a lot, when you look at twenty, thirty years ago, yes, it was 
fifteen, twenty thousand dollars; it was much more difficult. And now it 
has remained the same, so in actual dollars, it’s much cheaper.”98 This 
physician stressed that the bulk of profits from fertility treatment go into 
the pockets of other parties, including pharmaceutical providers, and that 
fertility providers—and physicians in general—are not as well-off as 
most would believe: 
[W]hile the cost of being a physician is going up, the average 
physician comes out with $250,000 of debt. . . . A lot of people 
have this thing on their mind, that physicians are super-rich, 
and . . . the average physician earns eighty-five, a hundred 
thousand bucks. . . . Three elements are making the money 
here[:] . . . the hospitals, the pharmaceutical [industry], and the 
medical devices. . . . The doctors have been used as a scapegoat 
in the health care system debate because the doctors, as I told 
you, we’re not good collaborators, so it’s a weaker link.99 
In the future, some fertility professionals believe that prices for IVF will 
remain fairly stable. “[I]t’ll either have to stay the same or decrease. I 
don’t think that people can carry an increase in the cost,” opined the 
executive in a fertility management organization: 
[I]f you look at third-parties, where patients are spending 
twenty, thirty thousand for a single cycle . . . . I don’t think that 
patients can afford more than that. And I do think that there’re 
going to be more financial programs that come into effect, that 
                                                     
97. Bernard, supra note 22. 
98. Interview with Physician One, supra note 65; see also The Costs of Infertility Treatment, 
RESOLVE, http://www.resolve.org/family-building-options/making-treatment-affordable/the-costs-
of-infertility-treatment.html [https:// perma.cc/F7RV-CR64] (last visited Feb. 17, 2016) (supporting 
Physician One’s assertions). 
99. Id. 
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help patients actually pay for it.
100
  
If the market will not bear an increase in IVF cost, this leaves the 
question of who will pay for innovations, and how. The executive in a 
fertility-related nonprofit remarked: 
Here’s the problem with all these great new things that are 
gonna come down the pipe. They’re gonna add cost. . . . [If] 
you’re gonna add on some of these things that could potentially 
bring a standard old IVF cycle, with a few of these things 
to . . . now be . . . twenty to twenty-five thousand? I just don’t 
see it. So I think there’s gonna have to be some sort of cost 
reduction at somewhere along the line.
101
 
The executive at a for-profit fertility pharmaceutical corporation, 
however, asserted that prices must drop: 
Everybody wants to “grow the market.” They all want a bigger 
piece of the pie. But the pie is only getting smaller. And the 
consolidation is helping with some of that, in keeping the 
volumes up inside the practices, and moving forward—but 
eventually, you can’t consolidate any more. You just have to 
become better at what you’re doing. And something has to 
happen to the price of IVF for these practices to continue to 
grow. . . . And this industry, these issues, these practices, are 
extremely profitable. And they’ve done that over the years 
because of the ability to set that price of managed care, where 
they have a pretty good reimbursement going. The cash market 
is just not gonna bear the price points that these physicians have 
put on their services. . . . [L]ook at Dr. [Name] in upstate New 
York, whose model has always been . . . “Cheap IVF.” . . . Dr. 
[Name] is . . . basing his practice model on “Hey, rich people 
can afford a $4,500 dollar cycle. Poor people can’t afford a 
$15,000 dollar cycle. And as long as I’m doing a good job, I 
don’t see the best success rates in the country, but as long as I’m 
on par with the national average, and I offer IVF at 4,500 
dollars, those richer couples are still going to come to me, 
because why pay $13,000 dollars for a procedure you can have 
done successfully for $4,500? They’re smart consumers. But if I 
don’t put my price there, I lose all of that middle-income couples 
[population].”102 
Greater insurance coverage would almost certainly increase the 
                                                     
100. Interview with Management Corporation Executive, supra note 57. 
101. Interview with Non-Profit Official, supra note 60. 
102. Interview with Pharmaceutical Corporation Executive, supra note 62. 
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supply of those seeking IVF, and it is likely to encourage further 
industry consolidation. The question is whether it would also spur the 
search for lower cost, higher volume services or whether increased 
demand would further segment the industry, encouraging new 
procedures with higher profit margins as well. 
C. The Future of Innovation 
The future of reproductive medicine innovation has two dimensions: 
(1) where will innovation occur, and (2) how will these innovations be 
implemented? Increasingly, innovations are coming not from fertility 
clinics but from entrepreneurial biotech startups such as OvaScience, and 
may be just as likely to be developed and tested outside the United States 
as inside national boundaries. Moreover, implementation of the 
innovations on the horizon may overlap with consolidation. 
Entrepreneurial companies may take advantage of consolidating clinics 
to market their innovations first to larger fertility clinics, which have 
greater patient volume as well as the financial and technological 
resources to purchase and implement these innovations. 
Innovation, which has traditionally occurred through university 
research centers or individual physician initiatives, may increasingly 
occur abroad or in more entrepreneurial start-ups that leverage 
jurisdictional differences. What may propel research abroad is the 
breakdown in the implicit American reproductive research bargain: 
almost no federal funding and almost no limit on privately funded 
research.
103
 Unlike other countries, American researchers do not require 
advance approval before they begin preliminary research into assisted 
reproduction.
104
 And unlike pharmaceutical companies, fertility clinics 
have not needed advance regulatory approval before trying new 
techniques such as IVF.
105
 This hands-off approach to reproductive 
innovations ended, however, when the Food and Drug Administration 
(FDA) asserted jurisdiction over cytoplasm transfers and cloning in the 
                                                     
103. See Kerry Lynn Macintosh, Brave New Eugenics: Regulating Assisted Reproductive 
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 271 (noting that 
the FDA claimed it had jurisdiction over “human cells used in therapy involving the transfer of 
genetic material by means other than the union of gamete nuclei”). 
104. Charo, supra note 38, at 507.  
105. See Mohammad Reza Sadeghi, How Should We Deal with the Barrage of New Infertility 
Treatments and Innovative Technologies?, 13 J. REPROD. & INFERTILITY 181, 181–82 (2012) 
(describing rapid rate of innovation and lack of clinical trials and testing for new fertility 
technologies). 
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late 1990s.
106
 
In 1996, the St. Barnabas Medical Center in New Jersey experimented 
with an effort to “rejuvenate” aging eggs by adding cytoplasm obtained 
from the eggs of younger women donors.
107
 The doctors, who had 
limited research funds, simply tried the technique on their patients.
108
 
The result produced thirty children worldwide, born using gametic 
material from three parents.
109
 Two out of eighteen fetuses developed 
Turner’s Syndrome, a chromosomal abnormality, and researchers 
speculated that it could have come from the technique or from the 
patient’s age.110 These children, however, did not inherit the donor DNA, 
but at least two other children in the group did.
111
 Ethicists objected to 
the prospect of germline genetic engineering—that is, the creation of 
children using DNA from a third party who would pass on the donor 
DNA to their own children
112—and the FDA, alarmed at the use of an 
untested technique of uncertain safety, asserted jurisdiction.
113
 The result 
effectively shut down this type of research in the United States, at least 
on humans.
114
 
                                                     
106. For a discussion of the FDA’s jurisdiction in such matters, see Richard A. Merrill & Bryan J. 
Rose, FDA Regulation of Human Cloning: Usurpation or Statemanship?, 15 HARV. J.L. & TECH. 
85, 102 (2001). 
107. See Jody Lyneé Madeira, Conceivable Changes: Effectuating Infertile Couples’ Emotional 
Ties to Frozen Embryos Through New Disposition Options, 79 UMKC L. REV. 315, 316 (2010). 
108. Carbone, supra note 31, at 1920. 
109. The process used a fertilized egg from the intended parents with nuclear DNA from the 
intended mother and father, and added cytoplasm from a donor egg that would ordinarily contain the 
donor’s mitochondrial DNA. Jason A. Barritt et al., Epigenetic and Experimental Modifications in 
Early Mammalian Development: Part II, Cytoplasmic Transfer in Assisted Reproduction, 7 HUM. 
REPROD. UPDATE 428, 428 (2001).  
110. See Macintosh, supra note 103, at 272 (reviewing the safety debate). 
111. Barritt et al., supra note 109, at 429–30. The cytoplasm was intended to strengthen the 
function of, rather than replace, the cytoplasm of the egg from the intended mother, and the child 
would not necessarily express the donor’s DNA. Id. at 433. This process can be used with minimal 
or no transfer of mitochondrial DNA from the donor. See Jacques Cohen et al., Birth of Infant After 
Transfer of Enucleate Donor Oocyte Cytoplasm into Recipient Eggs, 350 LANCET 186, 187 (1997). 
112. See John A. Robertson, Oocyte Cytoplasm Transfers and the Ethics of Germ-Line 
Intervention, 26 J.L. MED. & ETHICS 211, 211–13 (1998) (describing the various techniques). 
Researchers did find mitochondrial DNA from the donor in two of the children born using the St. 
Barnabus procedure, but not the others. See Kim Tingley, The Brave New World of Three-Parent 
I.V.F., N.Y. TIMES (June 27, 2014), http://www.nytimes.com/2014/06/29/magazine/the-brave-new-
world-of-three-parent-ivf.html [https://perma.cc/BCV3-RPV5]. 
113. See Judith Daar, Multi-Party Parenting in Genetics and Law: A View from Succession, 49 
FAM. L.Q. 71, 74 (2015) (observing that after the FDA said in 2001 that any further use of 
cytoplasmic injection would require an Investigational New Drug application, the practice ceased 
throughout the United States). 
114. It has, however, been done in the United States in monkeys. See David Cyranoski, DNA-
Swap Technology Almost Ready for Fertility Clinic, NATURE (Oct. 24, 2012), 
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The farthest reaching developments have occurred abroad. In 
February 2015, Parliament authorized the United Kingdom regulatory 
body that oversees assisted reproduction to license clinics that wished to 
use three-party IVF to eliminate the risk of mitochondrial disease.
115
 The 
authorization is more restrictive than the St. Barnabas procedures used in 
the 1990s in that it is designed to deal only with mitochondrial disease, 
not the problems associated with aging eggs.
116
 Nonetheless, it allows 
the research to proceed to human trials that will produce children. 
In the United States, the FDA has started discussion of whether the 
procedure should be allowed here.
117
 Before Parliament acted, the United 
Kingdom required animal testing and human experimentation on 
embryos up until the fourteen-day stage.
118
 The FDA would similarly 
require clinical trials before authorizing the procedure, and the funding 
for such measures would presumably have to come from private 
sources.
119
 The lack of such private funding sources is what shut down 
developments when the FDA asserted jurisdiction over the St. Barnabas 
procedures, and it is unclear whether that funding now exists.
120
 
                                                     
http://www.nature.com/doifinder/10.1038/nature.2012.11651 [https://perma.cc/RE3B-PMYH]. This 
research continues in the lab, without use of public funds. See Tingley, supra note 112. 
115. James Gallagher, UK Approves Three-Person Babies, BBC NEWS (Feb. 24, 2015), 
http://www.bbc.com/news/health-31594856 [https://perma.cc/YN9Y-JXMW]. 
116. See Tingley, supra note 112. 
117. See Dina Fine Maron, Making Babies with 3 Genetic Parents Gets FDA Hearing, SCI. AM. 
(Feb. 25, 2014), http://www.scientificamerican.com/article/making-babies-with-3-genetic-parents-
gets-fda-hearing/ [https://perma.cc/AT8U-SLUB]. As this Article was going to press, the U.S. 
Institute of Medicine issued a report recommending that clinical investigations be authorized, but 
limited to the creation of boys, who could not transmit the donor genes to offspring. The report 
suggested guidelines for such investigations, including a requirement that the investigators secure 
funding for long-term monitoring of children born through use of the procedure. NAT’L ACADS. OF 
SCI., ENG’G & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL, SOCIAL, AND 
POLICY CONSIDERATIONS (2016) [hereinafter MITOCHONDRIAL REPLACEMENT TECHNIQUES], 
http://iom.nationalacademies.org/reports/2016/Mitochondrial-Replacement-Techniques 
[https://perma.cc/GB78-QJXP]. Nonetheless, a provision in the Consolidated Appropriation Act of 
2016 may bar the procedure even if the FDA approves it. Joel Achenbach, Ethicists Approve ‘3 
Parent’ Embryos to Stop Diseases, but Congressional Ban Remains, WASH. POST (Feb. 3, 2016), 
https://www.washingtonpost.com/news/speaking-of-science/wp/2016/02/03/to-prevent-disease-
ethicists-approve-creation-of-embryos-with-three-genetic-parents/ [https://perma.cc/W2UX-6MDP].  
118. See Gallagher, supra note 115. 
119. See J. Ravindra Fernando, Three’s Company: A Constitutional Analysis of Prohibiting 
Access to Three-Parent In Vitro Fertilization, 29 NOTRE DAME J.L. ETHICS & PUB. POL’Y 523, 527 
(2015) (describing FDA approval process that includes searching review of the method’s safety and 
efficacy as well as satisfactory completion of human trials).  
120. See Tingley, supra note 112 (discussing funding available for stem cell research). “While the 
creation of human embryos for research is not prohibited under federal law in the United States 
(although some states are more restrictive), neither FDA nor any other agency of the U.S. 
Department of Health and Human Services can financially support such research where embryos are 
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In the meantime, other research is moving abroad, hoping to establish 
that medical procedures work in other jurisdictions before attempting to 
use them in the United States. The owners of biotech start-up 
OvaScience have expressed their frustration with U.S. procedures. They 
observe that there have not been any significant improvements in IVF in 
more than two decades.
121
 The most pressing issues involve egg quality, 
such as aging eggs that fail to produce pregnancies or women who for a 
variety of reasons fail to produce mature eggs capable of reproducing. 
New experimentation builds on the earlier procedures; some scientists 
would like to refine the process of cell “rejuvenation,” perhaps adding 
some of the intended mother’s own, healthy mitochondria to her eggs.122 
Other experimenters propose taking a woman’s immature eggs and 
allowing them to develop outside her body, or using a woman’s stem 
cells to create entirely new eggs.
123
 Extracting stem cells—or immature 
eggs—from a patient might be cheaper and less intrusive than extracting 
mature ova, and it would extend women’s reproductive lives. Scientists 
expect egg production to be the new frontier for assisted reproduction.
124
 
In 2013, OvaScience proposed to commercialize a new treatment it 
called “Augment” that would boost egg quality by using a woman’s own 
mitochondria.
125
 When it announced plans to do so, the FDA asserted 
that rather than treat the process as a medical procedure, subject to light 
regulation, it would subject the treatment to its more rigorous standards 
for drug development.
126
 The company’s share price tanked as a result, 
                                                     
destroyed, discarded, or subjected to risks with no prospect of medical benefit for the embryo.” 
George Dvorsky, US Experts Say Three-Parent Babies Are Okay—Just No Girls, GIZMODO (Feb. 3, 
2016, 6:11 PM), http://gizmodo.com/us-experts-say-three-parent-babies-are-okay-just-no-gir-
1756947506 [https:// perma.cc/64Z5-DGRG] (quoting MITOCHONDRIAL REPLACEMENT 
TECHNIQUES, supra note 117, at 24). 
121. Don Seiffert, OvaScience Advances Fertility Treatments Quickly Outside the U.S., BOS. BUS. 
J., http://www.bizjournals.com/boston/blog/bioflash/2014/09/ovascience-advances-fertility-
treatments-quickly.html?s=print [https://perma.cc/F9UB-ZU2J] (last updated Sept. 2, 2014, 3:05 
PM). 
122. See Jonathan L. Tilly & David A. Sinclair, Germline Energetics, Aging, and Female 
Infertility, 17 CELL METABOLISM 838, 838–50 (2013) (describing rejuvenation of eggs).  
123. See Dori C. Woods & Jonathan L. Tilly, The Next (Re)Generation of Ovarian Biology and 
Fertility in Women: Is Current Science Tomorrow’s Practice?, 98 FERTILITY & STERILITY 3, 6–7 
(2012) (describing the potential for taking egg stem cells and using them to develop new mature 
eggs). 
124. Anita Slomski, Hard to Conceive, PROTO (Nov. 5, 2014), http://protomag.com/articles/ivf-
hard-to-conceive [https://perma.cc/5HLZ-W3US]. 
125. AumentSM Treatment, OVASCIENCE, http://www.ovascience.com/treatments/augment 
[https://perma.cc/KB2B-KM9E] (last visited Feb. 23, 2016).  
126. Seiffert, supra note 121. 
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but it dealt with the setback by moving commercialization abroad.
127
 
Today, Augment is still not available in the United States, but in May 
2015, OvaScience announced the birth of the first child born through use 
of the procedure in Toronto, Canada.
128
 It believes that the global market 
is large enough that it makes more sense to test the effectiveness of its 
products through human use and testing abroad. OvaScience’s chief 
scientific officer observed, “People get hung up on, it’s a U.S. thing 
versus outside (the U.S.), I think of it as, where are the patients?”129 And 
he concluded that, on a global basis, ninety percent of the IVF treatments 
occur abroad.
130
 
OvaScience represents a major change in the source of innovation in 
assisted reproduction. The company thinks of itself as an entrepreneurial 
firm, intent on changing the way innovation in fertility treatments 
occurs.
131
 It seeks to disrupt, not exploit, existing markets.
132
 It has 
attracted venture capital investors,
133
 and it is a publically traded 
corporation.
134
 Both groups—private equity investors and 
shareholders—tend to focus on short term results. If the company is 
successful, it may be acquired by a larger operation; if its early products 
founder, it may soon be out of business. In this context, the company 
approaches regulations as obstacles to circumvent. 
The FDA, which comprehensively regulates drugs, has typically taken 
a different approach to medical procedures and human tissue, and thus 
                                                     
127. Alison Motluk, IVF Booster Offered in Canada But Not in US, CTR. FOR GENETICS & SOC’Y 
(Jan. 14, 2015), http://www.geneticsandsociety.org/article.php?id=8304 [https://perma.cc/F3M6-
72RP]; OvaScience’s Fertility Technology in Limbo After FDA Demands IND Filing, EP VANTAGE 
(Sept. 12, 2013), http://www.epvantage.com/Universal/View.aspx?type=Story&id 
=455479&isEPVantage=yes [https://perma.cc/K8HC-KWRM]. 
128. First Baby Born with OvaScience’s Augment Fertility Treatment, OVASCIENCE INC. INV. 
REL. (May 7, 2015), http://ir.ovascience.com/mobile.view?c=251343&v=203&d=1&id=2045382 
[https://perma.cc/4VXC-6XMW]. 
129. Seiffert, supra note 121. 
130. Id. 
131. Id.; see also OvaScience Chief Executive Officer Selected Entrepreneur of the Year 2013 
Finalist for New England by Ernst & Young, OVASCIENCE (June 3, 2013), 
http://www.ovascience.com/news/article/ovascience-chief-executive-officer-selected-entrepreneur-
of-the-year-2013-f [https://perma.cc/Y8JU-5SJ3] (highlighting the successes of its executives as 
entrepreneurs). 
132. Seiffert, supra note 121. 
133. OvaScience, CRUNCHBASE, https://www.crunchbase.com/organization/ovascience 
[https://perma.cc/XX4L-5GHL] (last visited Feb. 5, 2016). 
134. Don Seiffert, Clinical Data May Not Win over OvaScience Skeptics—but Revenue Will, BOS. 
BUS. J. (June 17, 2015, 12:11 PM), http://www.bizjournals.com/boston/blog/ 
bioflash/2015/06/clinical-data-may-not-win-over-ovascience.html [https://perma.cc/Q2W8-WHPL]. 
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has had relatively limited involvement in IVF.
135
 It nonetheless intended 
its assertion of jurisdiction over human cloning and the St. Barnabas 
cytoplasm procedure to have an in terrorem effect;
136
 that is, the mere 
suggestion that the FDA would require review before the procedure 
could be done shut down such experimentation in the United States.
137
 
This has taken place in large part because of the lack of funding for 
testing that would satisfy the FDA’s safety and efficacy concerns. Such 
testing in the pharmaceutical arena is enormously expensive, and it has 
tended to focus private efforts on the development of “blockbuster” 
drugs, with large payoffs for the developers.
138
 The market for assisted 
reproduction is not only more limited; the lack of insurance coverage 
makes it harder to realize the types of profits that fuel pharmaceutical 
research. 
OvaScience dealt with the FDA assertion of jurisdiction by moving 
abroad and for the moment, the company and the agency are at 
loggerheads.
139
 OvaScience hopes that, by demonstrating success 
abroad, it will persuade the FDA to relent.
140
 The FDA, which has 
successfully shut down this type of research in the past,
141
 risks 
becoming irrelevant if the effect of its efforts are to push reproductive 
research abroad. But when OvaScience announced the birth of a baby 
born through use of Augment in Toronto, Canada, its share prices fell 
because industry analysts expressed concern about the lack of 
appropriate testing.
142
 An analysis of the company’s prospects, however, 
indicated that while the clinical data is not yet winning over skeptics, 
“revenue will.”143 The company’s business model effectively requires 
that it position itself to succeed in the global market if it wishes to 
                                                     
135. The FDA’s assertion of authority is itself controversial. See Macintosh, supra note 103, 273–
74; Merrill & Rose, supra note 106. 
136. Merrill & Rose, supra note 106, at 100 (“The predictable in terrorem effect of these 
statements was almost certainly intended . . . .”). 
137. Macintosh, supra note 103, at 270. 
138. See generally June Carbone, Ethics, Patents and the Sustainability of the Biotech Business 
Model, 17 INT’L REV. L. COMPUTERS & TECH. 203 (2003) (describing business model of drug 
development). 
139. Taryn Hillin, Why an Incredible New Method to Extend Fertility Is off Limits in the U.S., 
FUSION (Aug. 4, 2015, 5:54 AM), http://fusion.net/story/164309/new-fertility-treatment-ovascience-
augment-ivf-eggs/ [https://perma.cc/2YMY-S2C5]. 
140. See Seiffert, supra note 121. 
141. Daar, supra note 113, at 74 (discussing the FDA’s shut down of the earlier experimentation 
with cytoplasmic transfers). 
142. Seiffert, supra note 134. 
143. Id. 
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establish itself in the United States.
144
 In the meantime, however, 
OvaScience’s share price has been incredibly volatile, ranging from a 
high of $55.69 per share to a low of $7.90 per share over a fifty-two 
week period.
145
 
Once innovations are ready for the market, companies such as 
OvaScience will take advantage of larger clinic networks, produced 
through consolidation, to distribute innovations. As a result, larger 
clinics will be able to offer their patients higher-end services at more 
competitive prices. According to a top fertility nonprofit official, “people 
who are paying out-of-pocket . . . are requiring and requesting a higher-
quality end result.”146 This official sees innovations occurring not in the 
sense of a “big breakthrough on the medical side” but in “the devices, 
the testing.”147 But because larger firms “tend to be more willing to be 
test sites . . . or they’re early adopters, . . . widespread use on some of 
these things is gonna take a long time.”148 
In the early stages, the latest scientific advances will cost more, 
require better trained, more sophisticated staff and carry higher profit 
margins on the performance of what is likely to be, at least initially, a 
small number of procedures. Yet, these new procedures will offer some 
prospective parents their only chance of having a genetically related 
child. The high-end market may, accordingly, remain lucrative.
149
 
                                                     
144. Indeed, in an effort to reassure its investors, OvaScience emphasizes its international reach, 
with new agreements to distribute Augment in Spain, Latin America, Japan, and the U.K. Its press 
releases underscore the size of its partners, highlighting its relationship with IVI Valencia, “a 
leading IVF clinic in Spain that is part of the IVI Group of 38 clinics spanning nine countries, which 
is the largest IVF clinic network in the world” and the largest group of clinics in Japan. Press 
Release, OvaScience Reports Second Quarter 2015 Financial Results (Aug. 10, 2015), 
http://ir.ovascience.com/phoenix.zhtml?c=251343&p=irol-newsArticle&ID=2078484 
[https://perma.cc/CNN8-8LMY].  
145. See Ovascience Inc. Analyst Price Target Update, AM. TRADE J. (Oct. 16, 2015), 
http://www.americantradejournal.com/ovascience-inc-analyst-price-target-update/6127536/ 
[https://perma.cc/P6K9-4BV2].  
146. Interview with Non-Profit Official, supra note 60. 
147. Id. 
148. Id. 
149. SPAR, supra note 7, at 65 (observing there is still considerable room at the top end of the 
market). With greater fertility tourism, this will be true whether or not the procedure is permitted in 
a given jurisdiction. If the procedure proves safe and popular abroad, pressure will build to 
introduce it into the United States. If not, American clinics may feel greater pressure to have foreign 
offices in jurisdictions that allow the procedure. In either case, larger, more flexible, and multi-
jurisdictional clinics will be in a better position to leverage regulatory differences for their own 
benefit. 
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D. Globalization, Brokers, and Network Creation 
These forces—globalization, increasing economies to scale, and the 
potential to leverage jurisdictional differences—may ultimately come 
together to remake assisted reproduction. For providers, economies of 
scale are prompting the type of consolidation going on across the 
medical profession; larger entities in turn may try to serve a larger 
clientele though the right mix of higher volume, lower cost services, and 
high-end developments for those who can afford them. 
At the same time, consumers are becoming more sophisticated in their 
search for more affordable—or more custom-tailored—products.150 
Increasingly, they are recognizing jurisdictional differences in medical 
care pricing, quality, and service availability.
151
 Medical tourism, 
defined as “the travel of patients from the ‘home country’ to the 
‘destination country’ for medical treatment,” is a rapidly growing multi-
billion-dollar industry involving thousands of patients from the United 
States alone.
152
 The Centers for Disease Control and Prevention (CDC) 
estimates that 750,000 U.S. residents travel abroad for health care each 
year.
153
 In total, the 2014 worldwide market for medical tourism was 
estimated to be between $38.5 billion and $55 billion.
154
 
American patients travel abroad for health care for the same reasons 
that companies locate some of their activities overseas: prices may be 
more affordable and restrictions may be less onerous.
155
 And rather than 
try to stem the travel aboard, American medical providers have 
sometimes sought to take advantage of the opportunities for their own 
benefit. For example, Johns Hopkins Medical International entered into a 
joint venture with Panama City’s Hospital Punta Pacífica, which gave 
the Panamanian facility “the advantages of an internationally recognized 
brand and access to the expertise of U.S. medical practitioners regarding 
                                                     
150. Indeed, preliminary research in 2010 indicates that patients are using the internet to seek out 
care abroad, typically after having sought treatment in their home country. See Eric Blyth, Fertility 
Patients’ Experiences of Cross-Border Reproductive Care, 94 FERTILITY & STERILITY e11, e14 
(2010).  
151. Id. at e12–e13 (indicating that patients are motivated both by factors such as cost and waiting 
time and by availability of services such as oocyte donation). 
152. I. Glenn Cohen, Circumvention Tourism, 97 CORNELL L. REV. 1309, 1311 (2012). 
153. Medical Tourism, CTR. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/ 
features/medicaltourism/ [https://perma.cc/9LZU-WYWT] (last visited Feb. 5, 2016).  
154. Joseph L. Muzaurieta, Surgeries and Safaris: Creating Effective Legislation Through a 
Comparative Look at the Policy Implications, Benefits, and Risks of Medical Tourism for the 
American Patient, 29 TEMP. INT’L & COMP. L.J. 115, 116 (2015). 
155. Id. at 117.  
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best practices and patient safety.”156 In addition, some insurance plans 
are considering (or in a few cases have already implemented) programs 
that would incentivize or mandate their insured patients to use medical 
tourism.
157
 There have also been proposals to allow Medicare and 
Medicaid beneficiaries to use their benefits abroad, given the potential 
cost savings involved for government programs.
158
 
On a smaller scale, patients have also engaged in “fertility tourism” 
for similar reasons: to take advantage of lower prices abroad and/or to 
circumvent restrictions.
159
 International surrogacy, particularly in India, 
has perhaps attracted the most attention—and criticism.160 The price 
difference between services stateside and overseas creates enormous 
incentives to move surrogacy abroad. In India, for example, a surrogate 
who successfully gives birth typically makes between $5000 and $6000, 
“an amount that exceeds a typical salary for several years of ordinary 
labor in India.”161 The clinic, in turn, charges American medical tourists 
$15,000 to $20,000 for the entire process, which constitutes “between a 
third and a fifth of what clients would pay for a similar service in the 
United States.”162 It also generates more than $500 million per year in 
revenues for India, constituting a respectable part of that country’s 
overall economic growth.
163
 
Moreover, since many countries ban surrogacy, or limit it to married, 
                                                     
156. U.S. INT’L TRADE COMM’N, CARIBBEAN REGION: REVIEW OF ECONOMIC GROWTH AND 
DEVELOPMENT, at xix (2008). 
157. I. Glenn Cohen, Protecting Patients with Passports: Medical Tourism and the Patient-
Protective Argument, 95 IOWA L. REV. 1467, 1473 (2010). 
158. See generally DEAN BAKER & HYE JIN RHO, CTR. FOR ECON. & POL’Y RES., FREE TRADE IN 
HEALTH CARE: THE GAINS FROM GLOBALIZED MEDICARE AND MEDICAID (2009) (outlining a plan 
for globalizing Medicare and Medicaid programs); Jennifer Conley, Medicare and Medical 
Tourism: Saving Medicare with a Global Approach to Coverage, 21 ELDER L.J. 183, 218 (2013) 
(“Medical tourism is a viable way for Medicare to rein in out-of-control health care spending and 
costs.”). 
159. See, e.g., Blyth, supra note 150, at e11; Cohen, supra note 152, at 1323 (observing that 
reproductive restrictions have prompted significant amounts of medical tourism). 
160. See, e.g., Lisa C. Ikemoto, Reproductive Tourism: Equality Concerns in the Global Market 
for Fertility Services, 27 LAW & INEQ. 277, 282 (2009) (“The most troubling aspects of reproductive 
tourism arise from the use of third parties who furnish gametes and from surrogates who gestate 
babies for others. In fact, the strongest critics of these practices use the term ‘trafficking’ rather than 
‘tourism.’”). 
161. Cohen, supra note 152, at 1324–25; see also Pamela Laufer-Ukeles, Mothering for Money: 
Regulating Commercial Intimacy, 88 IND. L.J. 1223, 1272 (2013) (“Indian surrogates, in contrast to 
[American surrogates], demonstrate a very low level of education and economic earning power.”). 
162. Cohen, supra note 152, at 1325. 
163. Michele Goodwin, Reproducing Hierarchy in Commercial Intimacy, 88 IND. L.J. 1289, 1292 
(2013) (noting that $500 million a year of that revenue stays in India). 
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heterosexual couples,
164
 some couples find that they can have genetically 
related children only by going abroad.
165
 Many couples whose home 
countries provide no access to surrogacy come to the United States.
166
 
Stuart Bell, the chief executive of Growing Generations, a Los Angeles 
surrogacy agency, reported that four years ago, “only about 20 percent of 
its clients came from overseas, but now international clients are more 
than half.”167 Other agencies report similar trends.168 
Practices such as surrogacy and egg donation are controversial 
because of the risk of exploitation of the women involved and/or because 
of ethical objections to the practice wherever it occurs.
169
 This kind of 
travel—to evade restrictions in the home country—has been termed 
“circumvention tourism.”170 The expansion of fertility tourism, however, 
also involves factors common to globalization generally: efforts to 
leverage differences in price,
171
 to receive care from high quality, 
experienced and successful specialists,
172
 to access newly developed or 
niche treatments not widely available,
173
 or to find a cultural milieu more 
supportive than that in the home country.
174
 Cutbacks in insurance 
                                                     
164. See Cohen, supra note 152, at 1323. China, France, Germany, Italy, Japan, Pakistan, 
Portugal, Saudi Arabia, Spain, and Turkey ban all forms of surrogacy while other countries and 
some U.S. states prohibit only commercial surrogacy. Joseph Chamie & Barry Mirkin, Surrogacy: 
Human Right or Reproductive Exploitation?, YALE GLOBAL ONLINE (Oct. 28, 2014), 
http://yaleglobal.yale.edu/content/surrogacy-human-right-or-reproductive-exploitation 
[https://perma.cc/26W7-N4ND].  
165. See Debora Spar, Reproductive Tourism and the Regulatory Map, 352 NEW ENG. J. MED. 
531, 531 (2005). 
166. Tamar Lewin, Coming to U.S. for Baby, and Womb to Carry It: Foreign Couples Heading to 
America for Surrogate Pregnancies, N.Y. TIMES (July 5, 2014), 
http://www.nytimes.com/2014/07/06/us/foreign-couples-heading-to-america-for-surrogate-
pregnancies.html [https://perma.cc/7X8P-5JWT]. 
167. Id.; see also Blyth, supra note 150, at e11. 
168. Lewin, supra note 166; see also Blyth, supra note 150, at e14 (reporting increase in internet 
searches for surrogacy agencies). 
169. Ikemoto, supra note 160, at 130. 
170. Cohen, supra note 152, at 1311–12. 
171. Lack of insurance coverage tends to increase the willingness to go abroad. See Ikemoto, 
supra note 160, at 298. 
172. For example, “success rates” were a factor for some patients. See Blyth, supra note 150, at 
e13. Kimberly Mutcherson observes further that the “reputation that the United States has earned as 
a nation with wide accessibility to high-quality fertility care, for those who can afford the equally 
high price tag that accompanies such care” attracts patients here. See Kimberly M. Mutcherson, 
Welcome to the Wild West: Protecting Access to Cross Border Fertility Care in the United States, 
22 CORNELL J.L. & PUB. POL’Y 349, 364 (2012). 
173. See, e.g., supra Section II.C (discussing Augment, which is only available outside of the 
United States). 
174. See Ikemoto, supra note 160, at 286–87 (noting existence of clinics and destinations that 
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coverage or the adoption of more restrictive regulations may spur 
increased interest in reproductive travel.
175
 For example, when Italy 
adopted Europe’s most restrictive laws, some Italian doctors simply 
moved their clinics across the border to Switzerland and the international 
clientele in Spain grew substantially.
176
 Today, cross-border fertility 
travel in Europe is robust,
177
 and most observers expect it to continue to 
grow.
178
 
What remains to be seen is whether the globalization of ART will also 
reduce prices. The Low-Cost IVF Foundation, a Swiss non-profit, is 
seeking to develop fertility treatments that could assist women in the 
developing world. It is currently working with Zambia’s health ministry 
to set up an IVF program in Africa that would use clomiphene citrate 
(Clomid), a drug that provides a modest boost to ovulation and costs just 
$12 per attempt, instead of standard injectable gonadotropin drugs used 
in the United States that cost thousands per cycle.
179
 Though Clomid 
might not be as effective as injectable gonadotropins, for some women 
its lower price may mean the difference between access to some 
treatment and no treatment at all. Belgian researchers have experimented 
with cheaper equipment that produced results comparable to those from 
pricier, standard labs.
180
 And American doctors are attempting to 
streamline the egg collection process, hoping to cut IVF costs in half for 
most patients.
181
 As with Augment, biotech start-ups have begun to 
                                                     
emphasize their support for same-sex couples). 
175. The Guardian commented at the height of the recession: 
As the NHS cuts back on free treatment for the childless, lumping IVF with tattoo removal as 
an act of kindness rather than treatment for a disease, the competitive prices of private clinics 
overseas compared with their UK rivals will look ever more tempting. This weekend a number 
of them will be touting for business at the Fertility Show, now in its second year, at London’s 
Olympia. 
Sarah Boseley, Fertility Becomes Big Business as NHS Cuts Back on Treatment, GUARDIAN (Nov. 
5, 2010), http://www.theguardian.com/society/2010/nov/06/fertility-treatment-foreign-clinics 
[https://perma.cc/7D8V-SCZV]. 
176. Richard F. Storrow, Quests for Conception: Fertility Tourists, Globalization and Feminist 
Legal Theory, 57 HASTINGS L.J. 295, 325 n.134 (2005) (citing Tamsin Smith, Fertility Laws 
Frustrate Italians, BBC NEWS (Aug. 9, 2004), http://news.bbc.co.uk/2/hi/europe/3548242.stm 
[https://perma.cc/94DF-4L2U]). 
177. See Storrow, supra note 176, at 296–97. 
178. Mutcherson, supra note 172, at 355. 
179. Maybe Babies, ECONOMIST (July 19, 2014), http://www.economist.com/news/international/ 
21607881-vitro-fertilisation-once-seen-miraculous-now-mainstream-rich-countries-soon 
[https://perma.cc/Q9U9-KS7B]. 
180. Id. 
181. Great Expectations, ECONOMIST (Oct. 25, 2014), http://www.economist.com/news/science-
and-technology/21627560-new-procedure-may-halve-cost-vitro-fertilisation-great-expectations 
[https://perma.cc/JY93-4WTQ]. Indeed, the efforts of the Low Cost Foundation also focus on egg 
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create innovative procedures that have already been approved for use 
abroad, though not in the United States.
182
 
These developments suggest that ART will increasingly be seen as a 
global phenomenon. Innovations may come from around the world, and 
new developments may target diverse patient groups with varying needs 
and abilities to pay. Yet, these developments are still in their infancy, 
driven by innovative individual researchers and accessed by enterprising 
patient-consumers who seek out the treatments. And the services that 
grow the quickest are those with funding that is most readily available 
from better-off patients.
183
 Observers wonder whether fertility tourism, 
like medical tourism in general, will benefit from increased numbers of 
international brokers who can attest to quality, determine safety, and 
advise patients, or whether patients will become prey to less scrupulous 
operators, precisely because of the lack of the third parties such as 
insurance companies and government regulators.
184
 Today, the emerging 
market for brokers tends to focus on the supply of sperm, eggs, embryos, 
and surrogates, although that may change with the availability of three 
parent IVF in the UK or sex selection procedures in the United States.
185
 
Indeed, even within the United States, separate agencies that do not 
necessarily provide fertility treatments themselves often recruit sperm 
and egg donors and surrogates.
186
 
                                                     
collection. Its methods involve fewer drugs, less artificial stimulation of the woman’s ovaries, which 
both reduced costs and the physical and emotional damage to women from egg collection. While the 
initial results may be lower success rates, the researchers are optimistic that over the long term, the 
results may become comparable. See Boseley, supra note 175. 
182. Great Expectations, supra note 181.  
183. The Low Cost Foundation, for example, though it is partnering with an African Health 
Minister and has support from the World Health Organization, has struggled for funds. The 
Guardian, after interviewing Foundation researchers, observed, “[t]he only money for now is in the 
cash registers of the burgeoning commercial clinics around the globe – and it’s coming from 
patients who may have sold or mortgaged all they have in the world for the chance of a baby.” 
Boseley, supra note 175. 
184. A U.K. expert on cross-border reproductive services, for example, advises that Spain is 
“very good,” and the Czech Republic has labs that are inspected in accordance with high standards. 
But she recommends against going to the Ukraine or to Greece, where the regulatory body has not 
gotten off the ground because of a lack of funding. Id. 
185. Ikemoto, supra note 160, at 287 (emphasizing that reproductive services take place in a 
context broader than the doctor-patient relationship); see also id. at 291–92 (describing role of 
brokers in facilitating international services). 
186. KARA W. SWANSON, BANKING ON THE BODY: THE MARKET IN BLOOD, MILK, AND SPERM 
IN MODERN AMERICA 199 (2014) (observing that most sperm banks and egg donor agencies are for-
profit enterprises, selling over the internet, and focused more on recruiting patients than serving 
doctors). See generally RENE ALMELING, SEX CELLS: THE MEDICAL MARKET FOR EGGS AND 
SPERM (2011) (providing a comprehensive account of the recruitment of egg and sperm donors). 
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Nonetheless, connections established across all parts of the fertility 
business may ultimately contribute to a more globalized industry. First, 
individual clinics increasingly see the internet as a source of patients, 
and websites are designed to appeal to international patient audiences 
and to those seeking services, such as sex selection, that are not 
universally available.
187
 These appeals in turn contribute to word-of-
mouth information—and to satisfied customers who help recruit 
others.
188
 They may also contribute to niche markets for certain 
procedures, such as sex selection, which is widely available in the 
United States or mitochondrial transfer in the U.K.
189
 Second, as clinics 
become larger, they may establish multi-jurisdictional partnerships or 
affiliations. Lisa Ikemoto, for example, describes a relationship between 
an American clinic and a Romanian lab, which recruited egg donors in 
Romania, had the eggs fertilized in Bucharest and shipped back to the 
United States, allowing the patient to realize savings both in the price of 
the eggs and the medical procedures done abroad.
190
 She also mentions a 
Danish clinic with centers in two Danish cities, Lithuania, and several 
African countries.
191
 The Fertility Institutes’ homepage lists offices in 
New York and Los Angeles, a presence in the United States, Mexico, 
and India, and a network of over 240 associated U.S. and international 
fertility centers.
192
 Third, increasing numbers of brokers, whether third-
party internet sites, travel agencies, or fertility specialists offer to provide 
information or arrange trips involving clinics abroad.
193
 Such brokers 
have fueled the growth of international surrogacy and egg donation, and 
                                                     
187. Ikemoto, supra note 160, at 285–89; Blyth, supra note 150, at e13–14. 
188. See Blyth, supra note 150, at e14 (discussing the importance of internet information in 
prompting cross-border care). 
189. Meredith Leigh Birdsall, An Exploration of “The ‘Wild West’ of Reproductive Technology”: 
Ethical and Feminist Perspectives on Sex-Selection Practices in the United States, 17 WM. & MARY 
J. WOMEN & L. 223, 226 (2010) (describing that more and more couples from other countries are 
coming to the United States for sex-selection procedures that they are denied at home); see also 
supra notes 115–20 and accompanying text (describing FDA responses to U.K. authorization of 
three parent IVF to address mitochondrial disease). 
190. Ikemoto, supra note 160, at 290.  
191. Id. 
192. FERTILITY INSTS., http://www.fertility-docs.com/about-us/clinics-and-staff.php 
[https://perma.cc/F8LU-5H46] (last visited Feb. 5, 2016); International Programs, FERTILITY 
INSTS., http://www.fertility-docs.com/programs-and-services/international-programs.php 
[https://perma.cc/K6PL-5MF7] (last visited Feb. 9, 2016); see also PAC. FERTILITY CTR., 
http://www.pacificfertilitycenter.com/the-center/infertility-center [https://perma.cc/Y9BT-Z5M7] 
(last visited Feb. 5, 2016); International Patients, PAC. FERTILITY CTR., 
http://www.pacificfertilitycenter.com/treatment-care/international-patients [https://perma.cc/TA6V-
Z3A6] (last visited Feb. 5, 2016) (describing itself as having an independent affiliate in Japan). 
193. Ikemoto, supra note 160, at 291–92. 
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they could help fuel reproductive tourism more generally.
194
 
CONCLUSION 
Larger entities, better-established networks, more global clientele, or 
greater use of brokers may offer greater flexibility. Fertility clinics may 
need to become more nimble in adopting new technologies, acquiring 
the ability to custom tailor services to meet client demand, and 
functioning in markets that may simultaneously reward less expensive 
approaches that can generate greater volume and high-end products for 
those who can pay for them. David Sable observes that: 
I have seen countless business plans over the past couple of 
years describing various combinations of IVF centers in 
different parts of the country merging, gaining economies of 
scale, trying to maintain pricing power and protecting quality 
branding. This trend . . . will accelerate as the market expands 
and consumer decisions are made less by individual patients and 
more by a combination of large insurers assembling networks 
and Uber/Open Table/Zoc Doc aggregators efficiently helping 
patients find an appropriate clinic. As has occurred in many 
areas of medicine, business will move to big purchaser 
(insurer/payor/patient purchasing service) buying from big 
provider (hospital/mega clinic[]).
195
 
These developments suggest a market that will be even more 
segmented in the future. It may involve clinics that scan the globe for 
new developments that can be implemented in sophisticated, high profit-
margin offices while referring more cost-conscious patients abroad. At 
the same time, innovation may come from a mix of government-
sponsored and privately-initiated research. Ironically, government-
supported research may be most critical to the low cost procedures with 
the potential to expand care while private investment stakes out the 
lower volume, but higher profit-margin innovations. And the innovations 
may come from across the globe. For example, in September 2015, the 
French announced that they had produced human sperm in a lab for the 
                                                     
194. Id.; see also Nicole Grather & Adam May, Going Global for a Family: Why International 
Surrogacy Is Booming, AL JAZEERA AM. (May 12, 2014, 7:30 PM), 
http://america.aljazeera.com/watch/shows/america-tonight/articles/2014/5/12/going-global-
forafamilywhyinternationalsurrogacyisbooming.html [https://perma.cc/2LUY-U39H] (describing 
the role of brokers in the growth of fertility tourism); Jennifer Rimm, Booming Baby Business: 
Regulating Commercial Surrogacy in India, 30 U. PA. J. INT’L L. 1429, 1456–59 (2009) (describing 
the positive and negative roles of agencies in commercial surrogacy). 
195. Sable, supra note 91. 
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first time, and a French biotech start-up sought a patent for the process 
jointly with French National Center for Scientific Research.
196
 
These changes should ultimately remake not just the availability of 
fertility treatments, but the nature of the doctor-patient relationship. 
Administrators will need to be both medical professionals and business 
men and women. Their patients will also need to be consumers, able to 
shop the most appropriate and affordable treatments. States interested in 
securing the safety of their citizens will need to be aware of international 
as well as national developments. At the center of these developments 
will be information flows—how should we conceive of what doctors 
need to know and to tell patients versus what the patients can be 
expected (for better and worse) to find out on their own? With an 
international race to invest, profit, evade regulatory restrictions, and 
realize the future, the doctor-patient relationship will require ever more 
sophisticated ways to determine safety and preserve the capacity for 
meaningful choice. The physicians’ remarks quoted above illustrate that 
they are already conscious of the shifts that the fertility industry is 
currently experiencing and will continue to experience in the future. But 
such awareness merely complicates the picture. For example, will they 
communicate the risks and benefits of developments such as fertility 
tourism or technological innovations unavailable at their own clinics to 
patients? Is such information material to the project of informed consent, 
wherein physicians must inform patients about a treatment procedure’s 
risks, benefits, side effects, and alternatives? And how are these ethical 
responsibilities affected by the fact that certain treatment options may 
not be offered at a patient’s home clinic, or indeed, within the borders of 
the United States? The future of fertility treatments will increasingly take 
place within a global marketplace; yet, no global infrastructure exists for 
determining the safety or the ethical permissibility of the developments 
on the horizon. 
 
                                                     
196. Jonathan O’Callaghan, First Lab-Grown Human Sperm Technique Revealed by Scientists, IFL SCI. 
(Sept. 21, 2015), http://www.iflscience.com/health-and-medicine/human-sperm-created-lab-first-
time-scientists-claim [https://perma.cc/KCD4-NSMK]. 
